William P. Harris, MD
It was always my plan to work in cancer care, but I wanted to have broader medical training first, so I studied internal medicine before pursuing oncology. This background has proven valuable for helping me understand a patient’s entire medical history and manage the full scope of the difficult problems they face as part of a cancer diagnosis. Oncology is a unique specialty; I feel that we, as cancer physicians, are positioned to practice a delicate balance of the art and science of medicine.
I believe in designing a treatment plan based upon the specifics of your unique case: the biology of your disease, your lifestyle preferences, how aggressively you want to approach the cancer and the risks you’re prepared to take to get the best results. I get to know my patients well. It’s an important part of guiding them through some very big and complicated decisions. Sometimes those decisions involve whether to participate in clinical trials, which provide access to new, promising therapeutic agents. Cancer therapy has come a long way, but there is still room for improvement. Trials can offer patients the latest advancements in care — and raise the bar for what will be the next standard of care.
Specialty: Medical Oncology
I am a board-certified oncologist who specializes in treating gastrointestinal cancers. These malignancies can affect the liver, bile ducts, gallbladder, pancreas, colon, rectum, anus, stomach and esophagus. I am a consultant for the Liver Tumor Clinic at UWMC and the SCCA’s multidisciplinary Pancreatic Cancer Specialty Clinic. I also serve as a moderator for UW 's Gastrointestinal Malignancy Tumor Board.
In addition to providing clinical care, I also design and conduct clinical trials. My research focuses on new targeted therapies, immunotherapies, novel drug combinations and other experimental therapies for patients with liver and biliary-tract cancers. Other areas of interest include analyzing data relating to treatment outcomes for patients with GI cancers and identifying new treatments for fibrolamellar hepatocellular carcinoma, a rare liver cancer that affects children and young adults.
We make promising new treatments available to you through studies called clinical trials led by SCCA doctors. Many of these trials at SCCA have led to FDA-approved treatments and have improved standards of care globally. Together, you and your doctor can decide if a study is right for you.
Many of our SCCA physicians conduct ongoing research to improve standards of patient care. Their work is evaluated by other physicians and selected for publication to the United States National Library of Medicine, the largest medical library in the world. See scientific papers this SCCA provider has written.
SCCA providers are often asked to give their medical expertise for press and news publications. Read articles by or about this SCCA provider.
SCCA’s William Harris, MD spoke with OncLive about updated phase 3 data from IMbrave150 study in hepatocellular carcinoma.
SCCA’s Dr. William P. Harris discussed the adoption of immunotherapy in advanced hepatocellular carcinoma.
Your care team
SCCA accepts most national private health insurance plans as well as Medicare. We also accept Medicaid for people from Washington, Alaska, Montana and Idaho. We are working to ensure that everyone, no matter what their financial situation, has access to the care they need.